Stephanie Hodson, MD
Hematology & Oncology · Meridian, IDNPI 1265478374
Payments from drug & device makers
Across 111 payments — averaging $49.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$2K
- CTI Biopharma Corp.$1K
- Johnson & Johnson$311
- Genentech USA, Inc.$219
- Amgen$193
- Gilead$158
- plus $2K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 1 | $1,630 |
| CTI Biopharma Corp. | 1 | $1,438 |
| Johnson & Johnson | 12 | $311 |
| Genentech USA, Inc. | 12 | $219 |
| Amgen | 10 | $193 |
| Gilead(2 entities) | 6 | $158 |
| Novartis | 7 | $143 |
| AbbVie | 3 | $139 |
| Incyte Corporation | 3 | $125 |
| Agios Pharmaceuticals, Inc. | 1 | $117 |
| Pfizer | 7 | $107 |
| AVEO Pharmaceuticals, Inc. | 1 | $100 |
| Foundation Medicine, Inc. | 1 | $92 |
| AstraZeneca | 6 | $75 |
| Sanofi | 5 | $73 |
| Beigene USA, Inc. | 1 | $63 |
| Seagen Inc. | 1 | $62 |
| EMD Serono, Inc. | 3 | $60 |
| Bristol Myers Squibb | 3 | $47 |
| Bayer | 3 | $46 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Lilly USA, LLC | 3 | $35 |
| Eisai Inc. | 2 | $32 |
| Merck | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Sobi, Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Springworks Therapeutics, Inc. | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $9 |
| Secura Bio, Inc. | 3 | $7 |
How this compares
$5,500 in reported general payments places this provider in the 35th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Meridian
- Sri Harsha TellaMeridian$8K
- Eric FountainMeridian$47
- Danko MartincicPost Falls$3.5M
- Bobby ChawlaCaldwell$1.1M
- Kerry PulverBoise$778K
- Dan ZuckermanBoise$537K
- William KreisleBoise$296K
- Christian ShullIdaho Falls$150K
- Ian QureshiNampa$49K
- Shane AhlersBoise$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.